Mainstay Medical has announced the limited US commercial launch of ReActiv8, its implantable restorative neurostimulation system to treat intractable chronic low back pain. The ReActiv8 system will be available through ReActiv8-certified physicians commencing in the summer of 2021.
“We are delighted to commercially launch ReActiv8 in the USA and make this innovative restorative neurostimulation therapy available to Americans suffering from intractable chronic low back pain,” said Jason Hannon, CEO of Mainstay Medical. “Supported by more than 10 years of clinical research, ReActiv8 is the only proven neurostimulation system to address mechanical intractable low back pain. Physicians will finally have access to a therapy to treat these patients beyond temporary treatments designed to merely mask the pain for a limited time.
“We are launching in a limited fashion to ensure we provide proper education to physicians and assist them in selecting the appropriate patients. We look forward to expanding the availability of ReActiv8 across the USA over the coming months and building on the momentum we have gained in Europe and Australia to continue to improve the quality of patients’ lives.”
To support the US commercial launch, Mainstay Medical has launched a new corporate website centred around patient and physician education. In addition to this, the company has introduced updated tools, guidance, and training materials to assist in identifying prospective patients for ReActiv8 therapy, educating physicians on the ReActiv8 system and becoming ReActiv8-certified, and helping patients access ReActiv8 in the USA.
Specific resources include physician training protocols and modules on ReActiv8, educational and marketing collateral, and informative videos that support and further physician education, patient identification, and appropriate product use.
“We are equipping ReActiv8-certified physicians with robust tools and information to enable proper patient identification and education. We expect that these resources will facilitate the identification of strong candidates for ReActiv8 and drive compelling patient outcomes,” added Hannon.